The global chronic pulmonary hypertension treatment market is expected to achieve a valuation of approximately US$ 7 billion in 2023, with forecasts indicating significant growth over the next decade. The market is projected to accumulate a value of US$ 11.4 billion by 2033, registering a compound annual growth rate (CAGR) of 5% during the forecast period from 2023 to 2033. The market recorded a CAGR of 3.5% during the historical period from 2018 to 2022.
The growth of the chronic pulmonary hypertension treatment market can be attributed to the increasing prevalence of this serious condition, which affects the arteries in the lungs and can lead to significant morbidity and mortality if left untreated. As awareness of chronic pulmonary hypertension rises, so does the demand for effective treatment options to improve patients’ quality of life.
Key factors driving market expansion include advancements in pharmacological therapies, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, which have significantly improved treatment outcomes for patients. Additionally, growing research and development initiatives aimed at discovering novel therapeutic options are enhancing the treatment landscape for chronic pulmonary hypertension.
North America currently dominates the chronic pulmonary hypertension treatment market, supported by a well-established healthcare system, significant investments in respiratory and cardiovascular research, and a high prevalence of chronic lung diseases. The Europe region is also experiencing considerable growth, driven by an increasing focus on early diagnosis and improved access to specialized care.
As the chronic pulmonary hypertension treatment market continues to evolve, stakeholders are expected to prioritize research and development efforts to introduce innovative therapies and enhance existing treatment protocols. The future of the chronic pulmonary hypertension treatment market looks promising, offering opportunities for improved patient care and effective management of this challenging condition.
What are the Challenges Faced by the Chronic Pulmonary Hypertension Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for chronic pulmonary hypertension is often high and can be a significant barrier to accessing care. The high cost of drugs, diagnostic tests, and medical procedures can make it difficult for patients to afford treatment, especially in low-income countries or for uninsured patients.
Furthermore, while there are several treatments available for chronic pulmonary hypertension, there is still a significant unmet need for more effective and targeted therapies. Some patients may not respond well to existing treatments, and there is a need for new drugs and treatment strategies that can improve outcomes for these patients.
Market Competition
Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.
In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH). The article, titled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension,” is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.
Key Companies Profiled
- Bayer, AG
- Attgeno AB
- Cereno Scientific AB
- Bial – Portela C S.A
- Liquidia Technologies
- Bellerophon Therapeutics
- AbbVie Therapeutics
- Insmed
- Altavant Sciences
- Lupin Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Inc.
- Teva Pharmaceutical Industries Ltd.
Key Segments Profiled in the Chronic Pulmonary Hypertension Treatment Industry Survey
By Drug Type:
- Endothelin Receptor Antagonists
- PDE-5 Inhibitors
- Prostacyclin Analogs
- SGC Stimulators
By Route of Administration:
- Oral
- Intravenous/Subcutaneous
- Inhalational
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
